Lipids Profile in Primary Hyperparathyroidism (LPHP)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT00961701 |
Recruitment Status
:
Terminated
(sample size was not enrolled)
First Posted
: August 19, 2009
Last Update Posted
: September 8, 2016
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease |
---|
Primary Hyperparathyroidism |
Severe traditional PHP has been associated with increased cardiovascular morbidity and mortality with an increase in acute MI prior to surgery.PHP is associated with increased prevalence of left ventricular hypertrophy, independent of blood pressure. Also prevalent in PHP, are valvular and myocardial calcifications as well as diastolic filling impairment, with a significant correlation with serum calcium and PTH levels.
Hypertension, dyslipidemia and impaired glucose metabolism were demonstrated in severe PHP, with improvement after surgery in these variables.Glucose tolerance test performed in patients with PHP revealed that 51% had impaired glucose tolerance, 34% had diabetes mellitus and 17% had impaired fasting glucose values. After successful parathyroidectomy fasting and 2-h plasma glucose falls significantly. Others have demonstrated hyperinsulinemia and impaired glucose tolerance without normalization after parathyroidectomy.
Most of the literature showing an increased cardiovascular risk is in those patients with more severe PHP .Patients with mild PHP had higher serum cholesterol, triglycerides, glucose, urate and hemoglobin values compared with controls.Also, moderate to severe vitamin D deficiency is a risk factor for developing cardiovascular disease especially in patients with hypertension.
Atherosclerosis is a diffuse disease formerly considered a lipid storage disease, which actually involves an ongoing inflammatory response. Elevated circulating levels of acute phase proteins, cytokines, and cell adhesion molecules indicate that inflammatory processes are occurring systemically . C-reactive protein [CRP] and the presence of metabolic syndrome were interrelated and were highly predictive for cardiovascular disease. Hyperinsulinemia was proposed as the common factor of all the traditional risk factors for cardiovascular disease, and insulin resistance is recognized as a chronic low-level inflammatory state.Although various inflammatory markers were individually significantly related to future cardiovascular disease risk, they added very little additional prognostic information to the traditional markers.
Recently, we have shown that greater probability of metabolic syndrome and insulin resistance were observed in patients with severe PHP. Serum calcium is a predictor of these cardiovascular risk factors.
Recent evidence suggests that the 'quality' rather than only the 'quantity' of LDL exerts a direct influence on the cardiovascular risk. LDL comprises multiple distinct subclasses that differ in size, density, physicochemical composition, metabolic behaviour and atherogenicity. There are at least four major subspecies of LDL (e.g. large LDL-I, medium LDL-II, small LDL-III, very small LDL-IV) and the predominance of small dense LDL has been accepted as an emerging cardiovascular risk factor .
Thus, the proposed study protocol is intended to evaluate lipoprotein phenotype and LDL size and subclasses in patients with primary hyperparathyroidism.
Study Type : | Observational |
Actual Enrollment : | 100 participants |
Observational Model: | Case-Only |
Time Perspective: | Cross-Sectional |
Official Title: | Atherogenic Lipoprotein Phenotype and LDL Size and Subclasses in Patients With Primary Hyperparathyroidism |
Study Start Date : | October 2009 |
Actual Primary Completion Date : | October 2010 |
Estimated Study Completion Date : | October 2016 |


Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years to 85 Years (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Sampling Method: | Probability Sample |
Inclusion Criteria:
- Patients with primary hyperparathyroidism
Exclusion Criteria:
- pregnant women
- patient taking hypolipidemic drugs
- patients with known cardiovascular, peripheral or cerebral atherosclerotic disease.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00961701
Israel | |
Endocrine Institute , Haemek Medical Center | |
Afula, Israel, 18101 |
Study Director: | Rafael Luboshitzky, MD | Endocrine Institute, Haemek Medical Center, Afula, Israel | |
Study Chair: | Manfredi Rizzo, MD | University of Palermo | |
Study Chair: | Giatgen Spinas, MD | University of Zurich | |
Study Chair: | Kaspar Berneis, MD | University of Zurich |
Responsible Party: | avraham ishay, Dr, HaEmek Medical Center, Israel |
ClinicalTrials.gov Identifier: | NCT00961701 History of Changes |
Other Study ID Numbers: |
0097.09EMC |
First Posted: | August 19, 2009 Key Record Dates |
Last Update Posted: | September 8, 2016 |
Last Verified: | September 2016 |
Additional relevant MeSH terms:
Hyperparathyroidism Hyperparathyroidism, Primary Parathyroid Diseases Endocrine System Diseases |